Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hemophilia B (Factor IX) (Apr 2021)

Trends That Matter for Copay Accumulator Programs

Radar On Market Access: UnitedHealth Reports 'Good Start to the Year,' But Expects COVID Earnings Hit Later

Radar On Market Access: Uber Partnership With ScriptDrop Heats Up Rx Delivery Space

MMIT Reality Check on Growth Hormone Deficiency (Apr 2021)

Perspectives on ACA Subsidy Expansion

5 Things to Consider When Launching a New Drug: MMIT Meet the Expert webinar recap on Predicting Payer Uptake with Precision

Radar On Market Access: Evernorth Drug Trend Report Highlights Pandemic's Impact on Utilization

MMIT Reality Check on Acute Myeloid Leukemia (Apr 2021)

Trends That Matter for Partial Orphan Drugs

Radar On Market Access: Interoperability Mandate Could Be an Opportunity for Payers

Radar On Market Access: Study Highlights Promise of Bundled Payments in Employer Plans

MMIT Reality Check on COPD (Apr 2021)

Perspectives on Cigna's MDLive Deal

Radar On Market Access: PBM Regulation, Rebate Rule Are High on Legislative Agenda

Radar On Market Access: New Administration's Stance on Copay Accumulators Remains Unclear

MMIT Reality Check on HeFH (Mar 2021)

Trends That Matter for New Heart Failure Drugs

Radar On Market Access: Health Insurers May See Earnings Hit From COVID Vaccine Reimbursement Hike

Radar On Market Access: How Will Subsidy Expansion Impact ACA Marketplaces?

MMIT Reality Check on Immune Globulin (PID) (Mar 2021)

Perspectives on Stock Selloff Following CVS 4Q Earnings Report

Radar On Market Access: Orphan Drug Act Has Been Overused, A New Study Shows

Radar On Market Access: Ohio Names New Medicaid PBM, Sues One of Current Vendors

MMIT Reality Check on Non-Small Cell Lung Cancer EGFR Mutated (Mar 2021)

Trends That Matter for New Prostate Cancer Treatment

Radar On Market Access: Cigna's Evernorth to Acquire MDLive in Telehealth Expansion

Radar On Market Access: FDA's Breyanzi Approval May Not Change NHL Management

MMIT Reality Check on Crohn's Disease (Mar 2021)

Perspectives on Pass-Through Rebate Models

Radar On Market Access: 2020 Was 'Breakout Year' for Digital Engagement in Health Care

Radar On Market Access: New Heart Failure Drugs Offer More Therapy Options

MMIT Reality Check on HIV (Feb 2021)

Trends That Matter for Rx Benefits in Medicaid

Radar On Market Access: Analysts Downplay Stock Selloff Following CVS 4Q Earnings Report

Radar On Market Access: Aetna Plans to Return to ACA Exchanges

MMIT Reality Check on Type 2 Diabetes (GLP-1 and Combo) (Feb 2021)

Perspectives on Developments to Watch in Pharma

Radar On Market Access: Pass-Through Rebate Models Need to Demonstrate Value

Radar On Market Access: Publicly Traded Insurers Continue to Tout Pharmacy Divisions

MMIT Reality Check on Rheumatoid Arthritis (Feb 2021)

Trends That Matter for Prevention of HAE Attacks

Radar On Market Access: New Prostate Cancer Treatment Orgovyx Offers Oral Option

Radar On Market Access: Cigna, Humana Get Hit by Increased COVID-19 Costs in 4Q

MMIT Reality Check on Neutropenia (Feb 2021)

Perspectives on Centene, UnitedHealth M&A Activities

Radar On Market Access: More States Choose to Carve Out Medicaid Drug Benefits

Radar On Market Access: Vaccine Race, Regulatory Risk, Robust M&A Will Impact Drugmakers in 2021

MMIT Reality Check on Multiple Sclerosis (Jan 2021)

Trends That Matter for Epilepsy Medications' Market Access

Radar On Market Access: Though Care Utilization Rebounds, Insurers Still Face Uncertainty in 2021

Radar On Market Access: UnitedHealth: Health Care Spending Returned to Normal in 4Q

MMIT Reality Check on Macular Edema (Jan 2021)

Perspectives on Surprise Medical Billing Regulation

Radar On Market Access: PBMs Face More Regulatory Challenges Amid Chaotic Transition

Radar On Market Access: Centene to Bolster Pharmacy Services with Magellan Deal

MMIT Reality Check on Epilepsy (Jan 2021)

Trends That Matter for MCO's Role in COVID Vaccine Rollout

Radar On Market Access: Centene, UnitedHealth Ring in New Year With M&A

Radar On Market Access: FDA Approves First Oral Treatment for HAE Attack Prevention

MMIT Reality Check on Non-Small Cell Lung Cancer ALK+ or ROS1+ (Jan 2021)

Perspectives on New-to-Market Oral Drugs

Radar On Market Access: Supreme Court's ACA Ruling May Upend Biosimilars Market

Radar On Market Access: Despite New Approvals, Plans Still Favor Generics for Epilepsy

MMIT Reality Check on Metastatic Prostate Cancer (Dec 2020)

Trends That Matter for COVID Vaccine Distribution

Radar On Market Access: Surprise Medical Billing Comes to An End, Insurers Oppose Arbitration Mechanism

Radar On Market Access: PBMs Continue Integration, Face More Regulatory Challenges in 2020

MMIT Reality Check on Migraine Prevention (Dec 2020)

Perspectives on Amazon Pharmacy

Radar On Market Access: MCO Messaging Plays Key Role in COVID Vaccine Rollout

Radar On Market Access: Biden Probably Won't Roll Back New Prior Authorization Proposal

MMIT Reality Check on Breast Cancer HR+/HER2+ (Dec 2020)

Trends That Matter: Centene's ACA Expansion

Radar On Market Access: New-to-Market Oral Drugs May Not Always Have a Leg Up on Injectables

Radar On Market Access: First Round of Vaccines Are Expected to Be Free to the Public

MMIT Reality Check on Nonmetastatic Prostate Cancer (Dec 2020)

Perspectives on Biden Administration's Drug-Pricing Moves

Radar On Market Access: Employers Show Interest in Moving to ICHRAs

Radar On Market Access: Insurers Will Play Key Role in COVID Vaccine Distribution, Reimbursement

MMIT Reality Check on Ovarian Cancer (Dec 2020)

Trends That Matter for Growth Hormone Deficiency Treatments

Radar On Market Access: For PBMs, Amazon Pharmacy May Pose Only Indirect Threat

Radar On Market Access: MA Insurers Report Strong Performance, Predict Enrollment Growth

MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo) (Nov 2020)

Perspectives on CMS Insulin Demo

Radar On Market Access: Teledermatology Program Reduces Patient Wait Time But Doesn't Increase Utilization

Radar On Market Access: Centene Expands ACA Footprint But Faces More Competition

MMIT Reality Check on Multiple Myeloma (Nov 2020)

Trends That Matter for Employer Health Benefits

Radar On Market Access: Insurer-Affiliated PBMs Propel Parent Firms' Revenues in Third Quarter

Radar On Market Access: Biden Administration's Drug-Pricing Moves May Be Limited

MMIT Reality Check on Cystic Fibrosis (Nov 2020)

Perspectives on MA Star Ratings

Radar On Market Access: What's Next for Health Insurers in a Likely Split Congress?

Radar On Market Access: Humana Reports Strong Earnings, But Expects Fourth-Quarter Loss

MMIT Reality Check on Chronic Lymphocytic Leukemia (Nov 2020)

Trends That Matter for Major PBMs' 2021 Formulary

Radar On Market Access: FDA's Approval of Sogroya May Change GH Class Management

Radar On Market Access: Centene Talks ACA's Future, Medicaid Rates in 3Q Earnings Call

MMIT Reality Check on Hepatocellular Carcinoma (Oct 2020)

Perspectives on the Future of ACA

Radar On Market Access: Employers Aim to Narrow Networks, Emphasize COEs, Expand Virtual Care Benefits

Radar On Market Access: Costlier PDPs, Cheaper MA-PDs Participate in CMS Insulin Demo

MMIT Reality Check on Psoriasis (Oct 2020)

Trends That Matter for CAR-T Therapies

Radar On Market Access: Racial Disparities Are Highlighted by Pandemic

Radar On Market Access: Average MA Star Ratings Fall Due to Increased Weights, Cut Points

MMIT Reality Check on Hemophilia A (Factor VIII) (Oct 2020)

Perspectives on Provider Consolidation

Radar On Market Access: Trump's $200 Medicare Drug Card Proposal Prompts Criticism

Radar On Market Access: CVS, OptumRx Exclude Brand-Name Inhalers From 2021 Formularies, Switch Up Diabetes Supplies

MMIT Reality Check on IBS-C (Oct 2020)

Trends That Matter on Trump Administration's Rebate Order

Radar On Market Access: COVID-19 Pandemic May Lower Health Care Costs, But Deferral Impact Exists

Radar On Market Access: If Preexisting Condition Protections Vanish, Health Insurers Probably Won't Cheer

MMIT Reality Check on Merkel Cell Carcinoma (Oct 2020)

Perspectives on Amazon-Sharp HealthCare Deal

Radar On Market Access: New Manufacturing Approach May Drive Down CAR-T Therapies' Prices

Radar On Market Access: Experts Remain Skeptical That SCOTUS Will Scuttle Entire ACA

MMIT Reality Check on Sickle Cell Disease (Sep 2020)

Trends That Matter for COVID Cost-Sharing Waivers

Radar On Market Access: Pandemic, Market Stability Encourage Major Insurers to Expand ACA Footprints

Radar On Market Access: As Payer M&A Slows Down, What's Next?

MMIT Reality Check on Schizophrenia (Sep 2020)

Perspectives on PBM Performance Amid COVID-19

Radar On Market Access: Prime Therapeutics Introduces Real Time Benefit Tool

Radar On Market Access: Trump's International Drug Pricing Order Is Still Missing; Rebate Order Draws Fire

MMIT Reality Check on Acute Migraine (Sep 2020)

Trends That Matter for Large Employers in 2021

Radar On Market Access: Amazon Moves Further Into Health Care Data, Sharp Deal Shows

Radar On Market Access: Some COVID Cost-Sharing Waivers Would Expire Soon

MMIT Reality Check on Breast Cancer HR+/HER2- (Sep 2020)

Perspectives on Telehealth Executive Order

Radar On Market Access: Insurers Expand Flu Vaccination Outreach to Blunt COVID-19 Effects

Radar On Market Access: USPS Delivery Slowdown Is Unlikely to Cause Major Rx Fill Disruption

MMIT Reality Check on Non-Small Cell Lung Cancer Systemic Therapy (Aug 2020)

Trends That Matter for Prostate Cancer Treatments

Radar On Market Access: Payers Face Challenges to Enroll Newly Uninsured

Radar On Market Access: Large Employers Expect Cost Uncertainty, More Virtual Care in 2021

MMIT Reality Check on Ulcerative Colitis (Aug 2020)

Perspectives on UnitedHealth, Humana's Chronic Conditions Programs

Radar On Market Access: COVID-19 Pandemic Amps Up Interest in Home Care

Radar On Market Access: Anthem, Cigna, CVS Report Strong PBM Performance Amid COVID-19

MMIT Reality Check on Duchenne Muscular Dystrophy (Aug 2020)

Trends That Matter for Major Insurers' Performance Amid COVID-19

Radar On Market Access: Trump Administration Issues Telehealth Executive Order, More Acts Are Needed

Radar On Market Access: FDA Approved Two PARP Inhibitors for Prostate Cancer

MMIT Reality Check on Parkinson's Disease (Aug 2020)

Perspectives on Remdesivir's $3,120 Price Tag

Radar On Market Access: Anthem Warns of Greater Commercial Enrollment Drop in Second Half

Radar On Market Access: Experts Are Skeptical of Trump Administration's Drug Pricing Executive Orders

MMIT Reality Check on Kidney Cancer (July 2020)

Trends That Matter for Medicaid MCOs

Radar On Market Access: UnitedHealth, Humana Launch Programs for Chronic Conditions

Radar On Market Access: Manufacturers, Payers Wait on Federal COVID-19 Vaccine Distribution Plan

MMIT Reality Check on Bipolar Disorder (July 2020)

Perspectives on Trump Admin's COVID-19 Testing Payment Guidance

Radar On Market Access: Despite Coronavirus Surge, UnitedHealth Expects Care Utilization to Rebound This Year

Radar On Market Access: Trump Admin's COVID-19 Testing Payment Guidance Stirs Debate

MMIT Reality Check on Psoriatic Arthritis (July 2020)

Trends That Matter for Racial Disparities in MA Plans

Radar On Market Access: IngenioRx Acquires ZipDrug to Improve Medication Adherence, Affordability

Radar On Market Access: Remdesivir's $3,120 Price Tag Stirs Debate

MMIT Reality Check on Acute Lymphoblastic Leukemia (July 2020)

Perspectives on MedImpact’s New Program to Accelerate Pharmacogenomics

Radar On Market Access: Upheld Transparency Rule Is Slated to Reshape Payer-Provider Negotiations

Radar On Market Access: Reports Show Medicaid MCOs Are 'Dominant,' Increase Affordability

MMIT Reality Check on Hemophilia A or B With Inhibitors (July 2020)

Trends That Matter for DMD Therapies

Radar On Market Access: Insurers Are Required to Cover Only 'Medically Necessary' COVID-19 Tests

Radar On Market Access: CMS Proposes New Medicaid Best Price Rules for Pricey Therapies

MMIT Reality Check on Ankylosing Spondylitis (June 2020)

Perspectives on COVID-19 Vaccine Rollout

Radar On Market Access: Telehealth Regulation and Reimbursement Issue Sparks Debates

Radar On Market Access: CMS Report Shows Increasing Racial Disparities in MA Plans

MMIT Reality Check on Urothelial/Bladder Cancer (June 2020)

Trends That Matter: Enrollment Shift Into ACA Exchanges

Radar On Market Access: Pricey Treatments Face Challenges on Cost Sharing and Data Analysis

Radar On Market Access: MedImpact’s New Program Aims to Accelerate Pharmacogenomics

MMIT Reality Check on Endometriosis (June 2020)

Perspectives on ACA Exchanges Amid COVID-19

Radar On Market Access: Uncertainties Over Effectiveness and High Costs Surround DMD Therapies

Radar On Market Access: 2021 MA, Part D Bids Face Challenges Amid COVID-19

MMIT Reality Check on Chronic Idiopathic Constipation (June 2020)

Trends That Matter: The Future of Value-Based Agreements

Radar On Market Access: 1.7K Plans Apply for Trump Admin's Fixed-Insulin-Copay Program for Seniors

Radar On Market Access: Payers and PBMs May Play Key Role in COVID-19 Vaccine Rollout

MMIT Reality Check on Narcolepsy (May 2020)

Perspectives on Surge of Mental Health Meds Use Amid COVID-19

Radar On Market Access: Will COVID-19 Advance Automatic Health Insurance Enrollment?

Radar On Market Access: COVID-19 Pandemic May Change Rx Delivery Permanently

MMIT Reality Check on Low Testosterone (May 2020)

Trends That Matter for Medical-Benefit Drug Spending

Radar On Market Access: COVID-19 Pandemic Drives Home Infusion Utilization

Radar On Market Access: PBMs See Solid 1Q Results Despite Challenges Ahead

MMIT Reality Check on Pain Narcotic Opioid (May 2020)

Perspectives on Coronavirus Antibody Testing

Radar On Market Access: COVID-19 May Drive More Insurers Into ACA Exchanges

Radar On Market Access: CVS Sees COVID Testing Sites as Part of Bigger HealthHUB Strategy

All posts

Learn more about MMIT's solutions

Posts by Topic

see all

Recent Posts

Subscribe to our blog

Payer Solutions

Pharma Solutions

Provider Solutions

Contact Us
info@mmitnetwork.com

© 2021 Managed Markets Insight & Technology, LLC
Privacy Policy